Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Generic warfarin: implications for patient care--another view.

Meyer M, Chan K, Bolton S.

Pharmacotherapy. 1998 Jul-Aug;18(4):884-6; discussion 887-9. No abstract available.

PMID:
9692670
2.

Generic warfarin: implications for patient care.

Wittkowsky AK.

Pharmacotherapy. 1997 Jul-Aug;17(4):640-3. No abstract available.

PMID:
9250543
3.

Reflections on generic warfarin.

Haines ST.

Am J Health Syst Pharm. 1998 Apr 1;55(7):729-33. No abstract available.

PMID:
9558427
4.

In favor of Coumadin over generic warfarin.

Benson SR, Vance-Bryan K.

Am J Health Syst Pharm. 1998 Apr 1;55(7):727-9. No abstract available.

PMID:
9558426
5.

Epistaxis associated with elevation of INR in a patient switched to generic warfarin--another view.

Meibohm B, Zhang W, Beierle I, Meyer MC.

Pharmacotherapy. 2000 Jul;20(7):866-9; discussion 869-71. No abstract available.

PMID:
10907982
6.

Does generic warfarin measure up?

Check W.

CAP Today. 1999 Jan;13(1):1, 30, 34-7. No abstract available.

PMID:
10339317
7.

Substituting warfarin products: what's the source of the problem?

Haines ST.

Ann Pharmacother. 2011 Jun;45(6):807-9. doi: 10.1345/aph.1Q063. Epub 2011 Jun 10.

PMID:
21666090
8.

Observational cohort study of switching warfarin sodium products in a managed care organization.

Swenson CN, Fundak G.

Am J Health Syst Pharm. 2000 Mar 1;57(5):452-5.

PMID:
10711525
9.
10.

Generic substitution: issues for problematic drugs.

Henderson JD, Esham RH.

South Med J. 2001 Jan;94(1):16-21. Review. Erratum in: South Med J. 2001 Dec;94(12):1235.

PMID:
11213935
11.

Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?

DeCara JM, Croze S, Falk RH.

Chest. 1998 Feb;113(2):261-3. No abstract available.

PMID:
9498932
12.
13.

Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians.

Pereira JA, Holbrook AM, Dolovich L, Goldsmith C, Thabane L, Douketis JD, Crowther M, Bates SM, Ginsberg JS.

Can J Clin Pharmacol. 2005 Fall;12(3):e229-39. Epub 2005 Oct 24.

14.

[Generic drugs, bioavailability, and bioequivalence].

Palma-Aguirre JA.

Gac Med Mex. 1998 Jul-Aug;134(4):491-4. Spanish. No abstract available.

PMID:
9789395
15.

[Prescription of generic drugs].

Cadórniga Carro R.

An R Acad Nac Med (Madr). 1997;114(3):495-509. Spanish. No abstract available.

PMID:
9549137
16.

Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers.

Bongiorno RA, Nutescu EA.

Semin Thromb Hemost. 2004 Dec;30(6):619-26.

PMID:
15630667
17.

Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: focus on warfarins.

Vercaigne LM, Zhanel GG.

J Pharm Pharm Sci. 1998 Sep-Dec;1(3):92-4. Review. No abstract available.

18.

Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin.

Yacobi A, Masson E, Moros D, Ganes D, Lapointe C, Abolfathi Z, LeBel M, Golander Y, Doepner D, Blumberg T, Cohen Y, Levitt B.

J Clin Pharmacol. 2000 Aug;40(8):826-35.

PMID:
10934666
19.

Comments on the note for guidance on bioavailability and bioequivalence in the European Union.

Calvo G.

Methods Find Exp Clin Pharmacol. 1998;20 Suppl A:11. No abstract available.

PMID:
9800721
20.

[Bioavailability and bioequivalence. Studies in healthy volunteers].

Sánchez García P.

An R Acad Nac Med (Madr). 1997;114(3):511-20. Spanish. No abstract available.

PMID:
9549138
Items per page

Supplemental Content

Write to the Help Desk